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Zefen Xiao, MD,* and Weibo Yin, MD*
Introduction: Primary small cell esophageal carcinoma (SCEC) is
a rare and aggressive disease for which there is no recommended
standard treatment at this time.
Methods: A total of 126 patients with SCEC, diagnosed histologi-
cally between May 1985 and June 2005 at our institution, were
analyzed retrospectively. All were staged according to the Veterans’
Administration Lung Study Group staging system. The TNM system
for esophageal carcinoma (6th edition, American Joint Committee
on Cancer) was also used for those who underwent esophagecto-
mies. SPSS (10.0) software was used for statistical analysis. Cox’s
hazard regression model was performed to identify prognostic fac-
tors. The Kaplan-Meier and log-rank methods were used to estimate
and compare survival rates. The 2 test was performed to examine
frequencies between different groups.
Results: Through a median follow-up of 13 months, 108 patients
died, 10 were alive, and 8 were lost to follow-up. Of the entire study
population, the overall median survival time (MST) and 1-, 3-, and
5-year overall survival rates were 12.5 months and 52.2%, 15.9%,
and 12.2%, respectively. For limited disease, the MST and 1-, 2-,
and 3-year overall survival rates were 14.0 months and 62.1%,
30.8%, and 22.4%, respectively; for extensive disease, the respective
values were 7.0 months and 29.3%, 13.6%, and 2.7% (p  0.0001).
The MST of 14.5 months for cases who received chemotherapy was
superior to that of 5.2 months for cases who did not (p  0.0001).
Tumor stage, length of the primary lesion, and chemotherapy, but
not surgery were independent prognostic factors in a multivariate
analysis.
Conclusions: SCEC is systemic disease. Tumor stage and chemo-
therapy were independent prognostic factors. Systemic therapy,
based on chemotherapy with radiotherapy, is recommended.
Key Words: Esophageal small cell carcinoma, Chemotherapy,
Prognosis.
(J Thorac Oncol. 2008;3: 1460–1465)
The lung has been considered the most common primarysite for small cell lung cancer (SCLC) since Barnard first
described it in 1926. Nevertheless, primary small cell gastro-
intestinal carcinoma accounted for 0.1 to 1.0% of malignant
gastrointestinal tumors, most of which were derived from the
esophagus. Small cell esophageal carcinoma (SCEC) was
first described in 1952, accounting for 0.4 to 2.7% of all
esophageal carcinomas1–3; it is a rare and aggressive carci-
noma, characterized by early dissemination. Surgical resec-
tion, radiation therapy, and multiagent chemotherapy have
been used alone and in combination. The prognosis for SCEC
remains poor, and there is no standard treatment at present.4–12
In this study, we retrospectively analyzed 126 cases of SCEC
treated at our institution between May 1985 and June 2005, to
identify prognostic factors, and we discuss the principles of
treatment.
PATIENTS AND METHODS
Between May 1985 and June 2005, a total of 126 SCEC
cases were treated at the Cancer Hospital of Peking Union
Medical College and the Chinese Academy of Medical Sci-
ences. The clinical records of these patients were analyzed
retrospectively. The study was approved by the Independent
Ethics Committee of the Cancer Hospital and Chinese Acad-
emy of Medical Sciences.
Patient Selection and Staging
All patients were questioned about their medical history
and underwent physical examinations. Chest radiograph, bar-
ium meal, Doppler ultrasound examination of the abdomen,
complete blood count, blood biochemistry analyses, and liver
and renal function evaluations were also performed. For cases
amenable to surgery, electrocardiograms and lung function
tests were also performed. Unless clinically indicated, brain
magnetic resonance imaging and radioactive isotope bone
scans were not performed. The World Health Organization
histologic criteria for small cell carcinoma were adopted. All
patients were diagnosed histologically before treatment. Most
of the postoperative specimens (70 cases) were rereviewed in
the study. All patients were staged as limited disease (LD) or
extensive disease (ED) according to the Veterans’ Adminis-
tration Lung Study Group staging system. Lesions confined
to the esophagus and adjacent organs with or without regional
lymph node involvement were classified as LD, whereas
lesions spreading beyond locoregional boundaries were clas-
sified as ED. The TNM system for esophageal carcinoma (6th
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edition, American Joint Committee on Cancer) was also used
for those who underwent esophagectomies.
Patient Characteristics
Between May 1985 and June 2005, 126 cases of SCEC
were diagnosed histologically at our institution, accounting
for 1.2% of esophageal carcinomas treated in the same
period. The patients had a median age of 58 years, with a
male to female ratio of 3.7:1. There were 119 cases with a
Karnofsky score more than or equal to 80. Complete blood
counts, blood biochemistry analyses, and liver and renal
function tests were within normal ranges for all except one
patient, who had moderate anemia before treatment. The
primary lesions were most often found in the middle third of
the thoracic esophagus and had a median length of 5.5 cm.
According to the barium meal, 55 cases were classified as
mushroom- or intraluminal-type. There were 36 cases of
combined types in the resected cases, who had preoperatively
been confused with squamous cell carcinoma. Of the total
cases, 85 were staged as LD and 41 were staged as ED (with
hematogenous metastases in 10 cases).
Of the 84 patients who underwent surgical resection, 8
cases were stage I; 16 cases, stage IIa; 10 cases, stage IIb; 40
cases, stage III; 4 cases, stage IVa; and 6 cases, stage IVb
(with hematogenous metastases in two). Sixty-two cases
(74%) of lymph node metastasis were detected among the 84
patients who underwent surgical resection; 30 cases (71%) of
distant lymph node metastasis with or without hematogenous
metastasis were also found at diagnosis in the cases without
resection (Table 1).
Treatment
Of the 126 cases, 84 received surgical resection, 63
received radiotherapy, and 88 received chemotherapy. Esoph-
agectomy (S) was performed alone in 22 cases. Radiotherapy
(R) was delivered alone in 12 cases, and chemotherapy (C)
was given alone in seven cases. Four cases were treated with
S R; 34 cases were treated with S C, including two cases
of preoperative chemotherapy; 24 cases were treated with S
 C  R; and 23 cases were treated with R  C. Of the 23
cases treated with R  C, 10 cases received chemotherapy
followed by sequential radiotherapy (including two cases of
salvage radiotherapy), 11 cases received radiotherapy fol-
lowed by sequential chemotherapy, and two cases received
concurrent chemoradiotherapy. The 38 cases treated with R
or S  R were defined as the local therapy group, and the 81
cases treated with S  C  R or R  C were defined as the
systemic therapy group. Chemotherapy started more than 2
months after local therapy was defined as delayed chemo-
therapy. There were only 14 cases of LD who received
chemotherapy first. Fourteen cases received delayed chemo-
therapy (nine in the S  C  R group, five in the R  C
group). In the nonresection group, there were more cases of
age more than or equal to 70 years, more cases located in the
upper third of the thoracic esophagus, and more cases with
ED. Nevertheless, there was no difference in any of these
factors between the chemotherapy and nonchemotherapy
groups.
Surgery
There were five cases of explorative resection, and 79
cases were treated by esophagectomy with two-field lymph
node dissection (the mediastinal and perigastric lymph
nodes), including 64 cases of R0 resection, 3 cases of R1
resection, and 12 cases of R2 resection.
Radiotherapy
Radiation was delivered by 6 or 8 MV photons, with a
conventional fraction (spinal cord dose, 40 Gy). A three-
dimensional conformal technique was used in only three
cases. Eight cases received adjuvant radiotherapy (preopera-
tive radiotherapy at a dose of 40 Gy in three cases). Twenty
cases received salvage radiotherapy. The target volume in 58
cases covered the primary lesion (at least 3 cm superiorly and
inferiorly and 1.5–2 cm bilaterally from the esophageal le-
sion) or the tumor bed with regional lymph nodes. The target
volume in five cases receiving postoperative salvage radio-
therapy included only the superclavicular fossa. Fifty-two
cases received a dose more than or equal to 50 Gy, eight
received a dose less than or equal to 40 Gy (four cases, 40
Gy), and the doses in five cases were unknown.
TABLE 1. Patients Characteristics
Characteristic
No. in Group
(% of Entire Group)
No. of
Surgery
(%)
No. of
Nonsurgery
(%) p
Age (yrs)
70 114 (90.5) 81 (96.4) 33 (78.6)
70 12 (9.5) 3 (3.6) 9 (21.4) 0.004
Gender
Male 99 (78.6) 65 (77.4) 34 (81.0)
Female 27 (21.4) 19 (22.6) 8 (19.0) 0.65
KS
80 7 (5.6) 2 (2.4) 5 (11.9)
80 119 (94.4) 82 (97.6) 37 (88.1) 0.074
Location
U 22 (17.5) 6 (7.1) 16 (38.1)
M 78 (61.9) 56 (66.7) 22 (52.4)
L 26 (20.6) 22 (26.2) 4 (9.5) 0.000
Lesion length
(cm)
5.0 59 (46.8) 41 (48.9) 18 (42.9)
5.0 67 (53.2) 43 (51.2) 24 (57.1) 0.53
Stage
LD 85 (67.5) 74 (88.1) 11 (26.2)
ED 41 (32.5) 10 (11.9) 31 (73.8) 0.000
Chemotherapy
Yes 88 (69.8) 58 (69.0) 30 (71.4)
No 38 (30.2) 26 (31.0) 12 (28.6) 0.78
Radiotherapy
Yes 63 (50.0) 28 (33.3) 35 (83.3)
No 63 (50.0) 56 (66.7) 7 (16.7) 0.000
KS, Karnofsky score; LD, limited disease; ED, extensive disease; U, upper third of
thoracic esophagus; M, middle third of thoracic esophagus; L, lower third of thoracic
esophagus.
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Chemotherapy
Sixty-seven cases received planned chemotherapy.
Fourteen cases received delayed chemotherapy in the sys-
temic therapy group. Three cases underwent single-agent
chemotherapy (capecitabine in one case and etoposide in
two), and 85 cases received combined chemotherapy (2–4
drugs). Regimens evolved from cyclophosphamide plus vin-
cristine plus mitomycin or not, plus etoposide (COMP or
COP) to cyclophosphamide plus adriamycin or epirubicin
plus vincas or etoposide (CAO or CAE), and further to
cisplatin or carboplatin plus etoposide (PE or CE); some
patients received alternating regimens. Forty-nine patients
received platinum-based regimens. The regimens in seven
cases were unknown (two cases in the S  C group, one case
in the S  C  R group, three cases in the R  C group, and
one case in the C group). A median course of six (range,
3–12) rounds of chemotherapy was given.
Statistical Analysis
Survival time was calculated from the start of treatment
to the point of death or the last follow-up. The failure sites
were classified as locoregional recurrence, or distant lymph
node or hematogenous metastasis or both. SPSS 10.0 soft-
ware was used to analyze prognostic factors by Cox’s hazard
regression model, with the entry factors of age (70 versus
70 years), gender, Karnofsky score (80 versus 80),
length of the primary lesion (5.0 versus 5.0 cm), stage
(LD/ED), surgery (yes/no), radiotherapy (yes/no), and che-
motherapy (yes/no). The 2 test was used to compare fre-
quencies. The Kaplan-Meier and log-rank methods were used
to estimate and compare survival rates. Survival curves were
also plotted (two-sided test with p  0.05).
RESULTS
By December 2005, through a median follow-up of 13
months, 108 patients had died, 10 were alive, and 8 were lost
to follow-up.
The overall median survival time (MST) and 1-, 2-, 3-,
and 5-year overall survival (OS) rates (SE) were 12.5
months (95% confidence interval CI, 10.3–14.7) and 52.2
4.5%, 25.2  3.9%, 15.9  3.4%, and 12.2  3.0%, respec-
tively (Figure 1). The MST (95% CI) and 1-, 2-, 3-, and
5-year OS (SE) for cases of LD versus ED were 14.0
months (11.4–16.6) and 62.1  5.3%, 30.8  5.1%, 22.4 
4.7%, and 16.8  4.3%, versus 7.0 months (5.7–8.3) and
29.3 7.1%, 13.6 5.5%, 2.7 2.7%, and 0%, respectively
(p 0.0001; Figure 2). The MST (95% CI) and 1-, 2-, 3-, and
5-year OS (SE) for cases with a primary lesion length less
than or equal to 5.0 cm versus cases with a length more than
5.0 cm were 15.0 months (11.3–18.7) and 67.4  6.1%,
34.1  6.3%, 21.3  5.7%, and 17.1  5.3%, versus 8.0
months (6.0–10.0) and 33.8  6.0%, 17.2  4.7%, 9.4 
3.6%, and 7.8  3.3%, respectively (p  0.0015; Figure 3).
The MST of 14.5 months for cases who received
chemotherapy was superior to that of 5.2 months for cases
who did not (p  0.0001; Figure 4), and this was true for
chemotherapy versus no chemotherapy for LD cases (17.0
versus 6.5 months; p  0.036), ED cases (9.5 versus 4.0
months, p  0.0001), stage II cases (29.0 versus 6.5 months,
p  0.022), stage III cases (13.0 versus 5.0 months, p 
0.0001), stage IVa cases (13.5 versus 2.5 months), and stage
IVb cases (9.5 versus 4.0 months, p  0.0002). Furthermore,
the MST was superior for cases who received planned che-
motherapy (16.0 months) compared with delayed chemother-
apy (11.0 months; p  0.017); for cases who received
systemic therapy (15.0 months) compared with local therapy
(5.2 months; p  0.0001); and for cases in the S  C  R
group (17.0 months) compared with cases in the S  R group
(5.0 months; p 0.0007). The MST for the R C group was
FIGURE 1. Kaplan-Meier curve of overall survival for the en-
tire group. Data from 126 cases of small cell esophageal carci-
noma histologically diagnosed at our institution between May
1985 and June 2005. By December 2005, 108 cases had died,
10 cases were alive, and 8 cases were lost to follow-up. Patients
with censored times are shown by tick marks.
FIGURE 2. Kaplan-Meier curve of overall survival compar-
ing patients with limited disease (continuous line) versus pa-
tients with extensive disease (discontinuous line). Patients
with censored times are shown by tick marks.
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borderline longer than that for the R group (p 0.077); when
excluding one patient who might have been at an early-stage
case in the R group, there was a statistical difference in the
MST between the R  C and R groups (p  0.033). The
difference between the MST of 13.0 months for cases who
underwent surgical resection and that of 9.5 months for cases
who did not was statistically insignificant (p  0.16), and
there was no difference in the MST between the S  C  R
and R  C groups (p  0.30; Figure 5). The MST of 13.0
months for stage IVa cases in the R  C group was equiv-
alent to that of stage III cases in the S  C  R group (p 
0.78). There was no statistical difference in the MST between
each subgroup with local therapy. The MST for stage I  II
cases (29.0 months) was longer than that for stage III  IV
cases (3.0 months) in the S C R group (p 0.0015). The
MSTs according to the different treatment groups are listed in
Table 2.
Two cases died during surgery. Esophageal perforation
occurred in two cases during treatment. One patient died of
treatment toxicity in the R  C group. Residual lesions were
detected in postoperative specimens for cases who received
preoperative radiotherapy or chemotherapy, but the lesions in
the irradiated fields were all obviously improved. The re-
sponse rate of 73.5% (25 of 34 evaluated cases) was high in
cases who received chemotherapy. One patient (LD, with a
lesion length of 3 cm) reached a complete response after four
courses chemotherapy of carboplatin plus etoposide; he died
55.0 months later from a local recurrence with lung metas-
tasis. Twelve cases survived more than 5 years, including
three in the S group (two cases in stage I and one in stage IIb),
one in the R group (LD, with a lesion length of 2 cm) who
received external irradiation with a dose of 50 Gy plus
intracavity irradiation (6 Gy, once a week, twice in total), six
cases in the S  C group (three cases each in stage IIa and
stage IIb), and two cases in the R  C group (one each of LD
and ED). The disease progressed with a median time of 3.0
months in the local therapy group (14 cases) and 8.0 months
in the systemic therapy group (59 cases).
The first failure sites in 73 cases included locoregional
recurrences in 13 cases, locoregional recurrences with distant
metastasis in 22 cases, and distant metastasis in 38 cases.
Distant metastasis occurred in 16 cases receiving local therapy
during treatment or at the first follow-up (1 month after treat-
ment). The patterns of recurrence according to different treat-
ment groups are shown in Table 3. There was no difference in
the frequency of locoregional recurrence between the S  C 
FIGURE 3. Kaplan-Meier curve of overall survival compar-
ing patients with an esophageal lesion length less than or
equal to 5.0 cm (continuous line) versus patients with an
esophageal lesion length more than 5.0 cm (discontinuous
line). Patients with censored times are shown by tick marks.
FIGURE 4. Kaplan-Meier curve of overall survival compar-
ing patients who received chemotherapy (continuous line)
versus patients who did not (discontinuous line). Patients
with censored times are shown by tick marks.
FIGURE 5. Kaplan-Meier curve of overall survival compar-
ing patients who received surgery plus chemotherapy plus
or not plus radiotherapy (continuous line) versus patients
who received radiotherapy plus chemotherapy (discontinu-
ous line). Patients with censored times are shown by tick
marks.
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R and R  C groups (p  0.385). Metastasis was most
frequently detected in the liver, and distant lymph node metas-
tasis was next most common. Of the seven cases in stage I or II,
one died during surgery, and 2 died of an accompanying disease
22.0 months and 127.0 months, respectively, after the operation.
In four cases in stage I (submucosal carcinoma), distant metas-
tasis occurred after the operation.
The length of the esophageal lesion (hazard ratio HR,
1.80; 95% CI, 1.20–2.71; p 0.005), the stage (HR, 1.94; 95%
CI, 1.27–2.96; p  0.002), and chemotherapy (HR, 0.42; 95%
CI, 0.28–0.64; p  0.000) were identified as independent
prognostic factors in a multivariate analysis. For postoperative
cases, pathologic TNM stage (HR, 1.64; 95% CI, 1.33–2.02;
p  0.000) and chemotherapy (HR, 0.35; 95% CI, 0.21–0.58;
p  0.000) were independent prognostic factors.
DISCUSSION
The clinical manifestations of small cell carcinoma of
the esophagus (SCEC) are similar to those of squamous cell
carcinoma of the esophagus (SC).2–15 The differential diag-
nosis is dependent on histopathologic examination. Bronch-
oendoscopic examination and a computed tomography scan
of the thorax should be performed to rule out SCLC. Because
of the small amount of preoperative tissue in the present
series, some patients were pathologically diagnosed preoper-
atively as SC, but postoperatively as SCEC combined with
SC. The available diagnostic techniques need to be improved.
Similar to the present results, Casas et al.6 showed that
there were significant differences in the MST between LD and
ED, as well as between patients with a tumor size less than or
equal to 5 cm and those with a tumor size more than 5 cm. As
Madroszyk et al.11 reported, the TNM stage should be used for
SCEC, instead of the length of the primary lesion and the
limited-extensive stage in the multivariate analysis for resected
cases in the present series, because the postoperative pathologic
TNM stage is an independent prognostic factor.
Surgical resection, radiation therapy, and multiagent che-
motherapy have been used alone and in combination. Neverthe-
less, the prognosis for SCEC remains poor, and there is no
standard treatment.4–5,7,10–11 The present study found that a few
cases in stage I  II might be curable by local therapy alone;
SCEC was primarily sensitive to chemotherapy or radiotherapy,
but the MST values for local therapy and chemotherapy alone
were poor and not significantly different. SCEC is a rare and
aggressive carcinoma that is characterized by early dissemina-
tion.1–15 Nemoto et al.8 reported that the frequency of metastasis
depended on the stage: 0% (0/3) in stage I, 75% (6/8) in stage II,
and 78% (7/9) in stage III and that the MST of patients who
received chemotherapy was significantly different from those
who did not. Casas et al.6 reported a significant difference in the
MST between patients who received systemic therapy and those
who received local therapy and found that chemotherapy was an
independent prognostic factor. As Nishimaki et al.,12 reported
four cases in stage I (submucosal carcinoma) who received
surgical resection alone died of visceral metastasis in the present
series. The MST for the systemic therapy group was superior to
that of the local therapy group, and the MST for cases who
received chemotherapy was longer, even in cases of stage II. In
addition, multivariate analysis identified chemotherapy and the
stage as major prognostic factors in the present study. Thus,
SCEC should be considered a systemic disease, and systemic
therapy, based on chemotherapy, should be administered even
for early-stage disease. Nevertheless, despite the often high
initial response rates, the disease frequently progressed shortly
after therapy. The development of appropriate regimens needs
further study.
Surgical resection was frequently the first choice in the
present series. It has been suggested that surgical resection
should be a part of systemic therapy for LD-SCEC.5,9,12–14
Medgyesy et al.5 considered that long-term survival was
lower after chemoradiotherapy because of fewer pathologi-
cally complete responses in combined-type SCEC. It has
been reported13–14 that several LD-SCEC cases, treated by
various adjuvant therapies with surgical resection, achieved
TABLE 2. Mean Survival Times According to Treatment Group
Treatment Group No. of Cases No. of LD (%) No. of ED (%) MST, mos (95% CI)
S 22 17 (77.3) 5 (22.7) 5.0 (3.9–6.1)
R 12 4 (33.3) 8 (66.7) 6.0 (3.3–8.7)
C 7 1 (14.3) 6 (85.7) 8.0 (4.2–11.8)
S  R 4 3 (75.0) 1 (25.0) 5.3 (1.9–8.7)
S  C 34 32 (94.1) 2 (5.9) 17.0 (9.8–24.2)
S  R  C 24 22 (91.7) 2 (8.3) 16.0 (12.2–19.8)
R  C 23 7 (30.4) 16 (69.6) 13.5 (11.2–15.8)
LD, limited disease; ED, extensive disease; CI, confidence interval; MST, median survival time; S, surgery; R, radiotherapy;
C, chemotherapy.
TABLE 3. Patterns of Recurrence According to Treatment
Group
Treatment
Group
No. of
Cases
MPT
(mos)
First Failure Site (No. of Cases)
Locoregional Distant
Locoregional
 distant
Total 73 6.0 13 38 22
S 9 2.2 — 6 3
R 5 5.0 — 4 1
C 4 6.3 1 2 1
S  C 16 5.8 — 12 4
R  C 18 9.8 6 7 5
S  R  C 21 9.0 6 7 8
MPT, median progression time; S, surgery; R, radiotherapy; C, chemotherapy.
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longer survival times. Sun et al.9 stated that cases in stage I 
II should be eligible for radical resection as part of systemic
therapy for SCEC. In the present study, although there were
more cases in ED in the nonresection group, there were no
statistical differences in the MST values between the resec-
tion and nonresection groups or between the S  C  R and
R  C groups. Given that there were more early stage cases
in the surgery group, the longer MST for stage I  II might
have contributed to the higher number of long-term survival
cases in that group. There was no difference in the frequency
of locoregional recurrence between the S  C  R and R 
C groups. Two advanced-stage cases in the R  C group
survived more than 5 years. In previous reports,4–5,7–8,10,15 13
cases in LD (of 41 cases) were long-term survivors with
chemotherapy plus radiotherapy. Thus, durable locoregional
disease control may also be achieved in cases who receive
radiotherapy. On the other hand, it is difficult for surgeons to
dissect superior mediastinal lymph nodes completely; there-
fore, radiotherapy was a salvage treatment in response to
locoregional recurrence for the 13 cases in the S  C  R
group. Imperfect resection may lead to delayed or even lost
opportunities for chemotherapy. Neither surgery nor radio-
therapy was an independent prognostic factor in the present
multivariate analysis.
The results from the present study support the
view4,6 – 8,10,15 that chemoradiotherapy, which is the standard of
care for LD-SCLC, should be the standard of care for LD-
SCEC. We also found that the MST for stage IVa cases in the
R C group was equal to that for stage III cases in the S C
R group. Durable disease control is known to be rare in cases
treated with chemotherapy alone.4–5,7,10–11 In addition, radio-
therapy might be more useful in SCEC than in SCLC to maintain
normal function of the esophagus for as long as possible. These
patients may also benefit from radiotherapy. The optimal target
coverage and dose are still unknown. Nemoto et al.8 indicated
that a dose of 60 Gy or higher may be appropriate as a radical
dose and that 40 to 50 Gy may be used as a prophylactic dose.
CONCLUSIONS
SCEC is a systemic disease, with stage and chemother-
apy as independent prognostic factors. Systemic therapy
based on chemotherapy with radiotherapy is recommended.
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